Business & FinanceBreaking NewsBreakingLatest News
Centre finalises 30% trade margin cap for 137 non-scheduled cancer drugs
Sentiment: NeutralHigh Priority
What Happened?
The Centre has set a 30% trade margin cap on 137 non-scheduled anti-cancer drugs to make them more affordable. This decision follows recommendations from an expert committee.
Key points
- The trade margin cap applies to both patented and non-patented drugs.
- Notable drugs affected include Nivolumab, Olaparib, Denosumab, and Topotecan.
- The cap is expected to reduce maximum retail prices by up to 70%.
- Revised prices will take effect from November 9, 2026.
- Manufacturers must display updated price lists on their websites.
- The NPPA found trade margins for non-scheduled cancer drugs ranged from 170% to 700%.
Key insights
- The cap could lead to significant savings for patients and healthcare systems.
- Increased transparency in drug pricing may enhance consumer trust.
- Future regulations may extend similar caps to other essential medicines.
Why it matters
This decision aims to make cancer treatments more accessible and affordable for patients.
Tags
Entities
Nivolumab· ProductOlaparib· ProductDenosumab· ProductTopotecan· ProductNational Pharmaceutical Pricing Authority· OrganizationDrugs (Prices Control) Order· RegulationIndia· Country
Source
Business Standard
